B+
Bull case
25%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
MNPR
Monopar TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.5
Score
AI commentary
The packet contains no recent-news or sufficient social sample, and the sentiment numbers are unmeasured placeholders, not observed neutral readings. The anchor fell from the prior baseline's $85.235 September 25 price to $77.97 on October 1, about 8.5%; the packet does not establish a cause. Analyst revisions and an earnings-surprise comparison are unavailable. Primary sources support regulatory progress, but independent coverage and forward visibility remain thin.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-05catalystALXN1840 AASLD abstracts and presentationsMedium impact
The company said two ALXN1840 abstracts were accepted for the November 5–9 meeting, with abstracts scheduled for public release October 5. Incremental clinical or regulatory significance is not yet established. [#IR-2026-08-19] Company release
2026-11-30eventComplete the rolling ALXN1840 NDA submissionHigh impact
Monopar began its Wilson disease NDA submission in July and said in August that it expected to complete it within the next few months. The date is an estimate; completion would not mean FDA filing acceptance or approval. [#PR-EARNINGS-2026-08-12] [#8-K-2026-08-12] Company release
2027-12-31catalystConditional FDA review and commercial transitionHigh impact
Monopar is preparing for a potential ALXN1840 launch. It reported $134.3 million in cash, equivalents and investments at June 30 and expected funding through at least December 2027. FDA acceptance, approval, reimbursement and uptake remain uncertain; the date is a monitoring horizon, not an announced decision date. [#PR-EARNINGS-2026-08-12] Company release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology